WESTLAKE VILLAGE, Calif., Sept. 17, 2018 Inspyr Therapeutics announced today that it has entered into an agreement with Ridgeway Therapeutics Inc. in which Ridgeway will license and assume control of certain assets relating to Inspyr's oncology development programs, including intellectual property rights relating to adenosine antagonists owned by Inspyr.
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial sales. In the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
About InspyrInspyr Therapeutics, Inc. is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases.
About Ridgeway Therapeutics Inc.Ridgeway is a privately held biotech company developing innovative T-cell focused precision therapies that address the unmet needs and limitations of currently available forms of treatment.
SOURCE Inspyr Therapeutics
Advertisement
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Advertisement
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial sales. In the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
About InspyrInspyr Therapeutics, Inc. is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases.
About Ridgeway Therapeutics Inc.Ridgeway is a privately held biotech company developing innovative T-cell focused precision therapies that address the unmet needs and limitations of currently available forms of treatment.
SOURCE Inspyr Therapeutics
